Benjamin Boyerinas

Benjamin Boyerinas has a diverse work experience in the field of oncology research and development. Benjamin is currently the Director and Head of Immuno-oncology at AvenCell since January 2022. Prior to this, they served as an Associate Director at 2seventy bio, a bluebird bio oncology spin-out, from November to December 2021.

Benjamin also had a significant tenure at bluebird bio, where they held various roles from 2014 to 2021. Benjamin started as a Scientist II from September 2014 to December 2015, then progressed to become a Senior Scientist in Oncology Discovery from January 2016 to October 2019. Finally, they served as an Associate Director of Research in Oncology Discovery from November 2019 to October 2021.

Before their time at bluebird bio, Benjamin worked as a CRTA Postdoctoral Fellow at the National Cancer Institute from February 2013 to September 2014. Prior to that, they held the position of Postdoctoral Fellow at the University of Chicago from January 2010 to January 2013 after completing their role as a Graduate Research Associate from September 2003 to December 2009.

Overall, Benjamin Boyerinas has a strong background and extensive experience in the field of oncology research and development, with notable positions at AvenCell, 2seventy bio, bluebird bio, the National Cancer Institute, and the University of Chicago.

Benjamin Boyerinas attended the University of Chicago from 2003 to 2009, where they obtained a Doctor of Philosophy degree in Cancer Biology. Prior to that, they completed their Bachelor of Science degree in Biology at Dickinson College, which they attended from 1999 to 2003. Additionally, in 2001 and 2002, Benjamin Boyerinas studied at the University of East Anglia, although the degree and field of study achieved during this period are not specified.